GlassScriptPhysician profile
Allan Lee Kurtz
NPI 1679656946
$13,069.94
in general payments reported to CMS, 2019-2025
69 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $2,294 · 2021: $2,424 · 2022: $1,581 · 2023: $1,486 · 2024: $1,849 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,037 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,037.24 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,805.24 | 2021-2025 | |
| Amgen INC. | $1,245.62 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $998.38 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $722.09 | 2019-2025 | Verquvo, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $630.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $587.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.81 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $522.89 | 2019-2024 | Xarelto |
| Allergan, INC. | $471.01 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $461.18 | 2019-2021 | |
| Novo Nordisk INC | $421.09 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $418.44 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $384.30 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $355.63 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $302.76 | 2019-2023 | Veozah |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Kurtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.